linjc16/ctgov huggingface dataset:
Effect of 12 Weeks of Acupuncture on AMH and COH in Low Responder Patients

Study Overview
=================
Brief Summary
-----------------
the investigators want to study whether 12 weeks of acupuncture has any effect on AMH and the ovarian reserve in women with low ovarian reserve (low responders). AMH is measured before and after 12 weeks of acupuncture and the clinical response to controlled ovarian hyperstimulation before and after the acupuncture is compared.

Detailed Description
-----------------
AMH is measured cycle day 2 or 3 before and after 12 weeks of acupuncture and the levels are compared. Furthermore, secondary outcomes from IVF treatments before and after the intervention are compared.

Official Title
-----------------
Effect of 12 Weeks of Acupuncture on AMH and Ovarian Reserve in Women With Low Ovarian Reserve. A Pilot Study

Conditions
-----------------
Hypogonadism; Ovarian, Female Infertility

Intervention / Treatment
-----------------
* Other: acupuncture


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: IVF/ICSI treatment 18-40 years AMH measured < or = 10 pmol/l maximum of 8 oocytes collected at last treatment before inclusion- Exclusion Criteria: (use of testicular sperm) more than 4 acupuncture treatments within the last 3 months before inclusion -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Interventional Model Description: comparison of AMH and ovarian response before and after acupuncture
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: acupucture arm<br>all participants undergo 12 weeks of acupuncture | Other: acupuncture<br>* 12 weeks of acupuncture comprising basic acupuncture, ear acupuncture and Moving cups. On top of the basic acupuncture, additional locations can be added.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AMH | anti-Müllerian Hormone level | chance from baseline after 12 weeks of acupuncture | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| No. of oocytes aspirated | the number of oocytes collected during egg aspiration for IVF | change from baseline treatment and after 12 weeks of acupunture | 
| FSH dose/oocyte collected |  | change from baseline treatment and after 12 weeks of acupuncture | 
| TQE 44 hours after fertilisation | The number of top quality embryos 44 hours after fertilisation | change from baseline treatment and after 12 weeks of acupuncture | 
| biobank with blood plasma |  | 2 years after treatment completion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
IVF, acupuncture, AMH, ovarian reserve
The Treatment of Clavicular Fractures

Study Overview
=================
Brief Summary
-----------------
Patients with a displaced, shortened, midshaft clavicular fracture are randomized in two groups: conservative or operative treatment. The conservative arm is treated with a sling for 6 weeks. The operative arm is treated with osteosynthesis, within 2 weeks. Patients are clinically and radiologically evaluated during 1 year. A economical analysis is also done.

Official Title
-----------------
The Treatment of Displaced, Midshaft Clavicular Fractures: Operative vs Conservative. A Prospected, Randomized Study

Conditions
-----------------
Displaced, Midshaft Clavicular Fractures

Intervention / Treatment
-----------------
* Procedure: osteosynthesis
* Other: sling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 to 65 year 100% displaced midshaft clavicular fracture shortening male: 18mm female: 14mm Exclusion Criteria: pregnancy pathological fracture open fracture history of frozen shoulder ipsilateral fracture of shoulder or scapula neurovascular injury contraindication to anaesthesia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>operative treatment | Procedure: osteosynthesis<br>* operative treatment<br>|
| Active Comparator: 2<br>conservative treatment | Other: sling<br>* conservative treatment<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Union |  | 1 year | 
| Functionality |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complications |  | 1 year | 
| Time to heal |  | 1 year | 
| Cost |  | 1 year | 
| Relation with medication |  | 1 year | 
| Relation with smoking |  | 1 year | 
| Relation with job |  | 1 year |
Predictive Factors in Response to Inhaled Corticoids in Chronic Cough

Study Overview
=================
Brief Summary
-----------------
The hypothesis is that a high fractional exhaled nitric oxide can predict the response to inhaled corticoids in chronic cough.

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: Budesonide novolizer
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: chronic cough Exclusion Criteria: active smoker treated by corticoids during the previous month use of angiotensin-converting-enzyme inhibitor

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Group Budesonide<br>Inhaled corticoids | Drug: Budesonide novolizer<br> <br> |
| Placebo Comparator: Group Placebo<br>Placebo by inhalation | Drug: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Leicester cough questionnaire |  | 5 minutes |
Evaluation of Recurrence Risk of Atrial Fibrillation After Cryoballoon Ablation

Study Overview
=================
Brief Summary
-----------------
The recurrence of atrial fibrillation(AF) after pulmonary vein ablation with cryoballoon is conducted by many factors . The previous studies found larger left atrial and longer AF duration are tied to higher risk of AF recurrence. The characters of ablation procedure is also of critical importance to durable clinical success such as temperature features and time-to-isolation (TTI). The aim of our study is to develop an tool of recurrence risk evaluation with both pre-procedure and procedure factors.

Official Title
-----------------
Evaluation of Recurrence Risk of Atrial Fibrillation After Cryoballoon Ablation： a Retrospective Cohort Study

Conditions
-----------------
Atrial Fibrillation

Intervention / Treatment
-----------------
* Device: cryoballoon ablation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with paroxysmal AF and accept cryoballoon ablation. Exclusion Criteria: left atrium (LA) diameter (anterior-to-posterior)>55mm on transthoracic echocardiography (TTE) the presence of thrombus in the LA or left atrial appendage (LAA) on transesophageal echocardiography (TEE) uncorrected heart failure (NYHA class III or IV), concomitant moderate or severe valvular heart disease or bioprosthetic valve, malignancy necessitating chemotherapy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ablation group<br> | Device: cryoballoon ablation<br>* Patients with AF will accept cryoballoon ablation.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the time to atrial fibrillation recurrent | the time to atrial fibrillation recurrent | 1year after the cryoballoon ablation |
Effect of Pneumoperitoneum Anterior Abdominal Wall Tissue Oxygenation

Study Overview
=================
Brief Summary
-----------------
During laparoscopic surgery, the abdomen is inflated with carbon dioxide for abdominal imaging and increased intraabdominal pressure affects intraabdominal structures and abdominal wall.

Detailed Description
-----------------
The investigators aimed to investigate the effects of pneumoperitoneum administered during laparoscopic cholecystectomy on abdominal wall oxygenation and postoperative pain scores.

Official Title
-----------------
Investigation of the Effect of Pneumoperitoneum Anterior Abdominal Wall Tissue Oxygenation on Laparoscopic Cholecystectomy

Conditions
-----------------
Laparoscopy, Abdominal Wall

Intervention / Treatment
-----------------
* Device: rso2


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who were in the American Society of Anesthesiologists (ASA) I-III class Underwent laparoscopic cholecystectomy Exclusion Criteria: Previous surgeon surgeon Local anesthetic allergy, Bleeding is a diathesis disorder Mental impairment, Allergic to the drugs used, Patients who are not reluctant to participate in the study, Presence of infection in the block area, Patients whose body mass index is over 30

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Interventional Model Description: prospective, cohort,double blind
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: rso2<br>The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins. | Device: rso2<br>* The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.<br>* Other names: abdominal wall tissue oxygenation;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| rso2 | The regional oxymetry probe (Medtronic Quick Assist INVOS™ (In-Vivo Optical Spectroscopy) Cerebral/Somatic Oximeter) will be placed in the abdominal region of the umbilicus in the middle clavicular line | perioperative | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual Analog Scale | Visual Analog Scale was used for pain.Pain intensity was measured using 0-10 cm visual analogue scale (VAS). (0=no pain, 10=intolerable pain) | Postoperative 24 hours | 
| analgesic use | analgesic use | Postoperative 24 hours |
Magnesium Sulfate vs Placebo for Placental Abruption

Study Overview
=================
Brief Summary
-----------------
To evaluate the safety and efficacy of magnesium sulfate for preterm suspected abruption.

Detailed Description
-----------------
We hope to learn if there is a difference in the efficacy of intravenous magnesium sulfate versus intravenous saline infusion in the resolution of vaginal bleeding and contractions in patients with a suspected placental abruption.

Official Title
-----------------
Randomized, Double Blind Trial of Magnesium Sulfate Tocolysis Versus Intravenous Saline for Suspected Placental Abruption

Conditions
-----------------
Abruptio Placentae

Intervention / Treatment
-----------------
* Drug: Magnesium Sulfate
* Other: Normal Saline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - vaginal bleeding and contractions consistent with suspected placental abruption between 24 and 34 weeks gestation. Exclusion Criteria: - preterm labor, severe bleeding necessitating immediate delivery, maternal coagulopathy, fetal distress

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Magnesium Sulfate<br>Magnesium Sulfate 4 gram bolus, followed by 2 grams per hour | Drug: Magnesium Sulfate<br>* Magnesium Sulfate 4 gram bolus, followed by a maintenance dose at 2 grams per hour. Rate increases up to 4 grams per hour may be administered per physician discretion.<br>* Other names: Active study drug;|
| Placebo Comparator: Normal Saline<br>Normal Saline 4 gram bolus, followed by 2 grams per hour | Other: Normal Saline<br>* Normal Saline infusion of 4 gram bolus, followed by 2 grams per hour with rate increases up to 4 grams per hour per physician discretion.<br>* Other names: Normal Saline infusion as placebo;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Undelivered With Resolution of Vaginal Bleeding and Contractions in First 48 Hours | The primary outcome was the proportion of women undelivered at 48 hours with resolution of vaginal bleeding and uterine contractions. | 48 hours after the randomization | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gestational Age at Delivery (Weeks) | Median gestational age at delivery (in full weeks) | Time of delivery | 
| Neonatal Apgar Score at 5 Minutes | The median Apgar score at 5 minutes. Apgar score scale is from 0 to 10 with score 0 expressing the worst neonatal status and score 10 the best status. | At 5 minutes after birth |
Immunity After COVID-19 Vaccination

Study Overview
=================
Brief Summary
-----------------
The purpose of the research is to evaluate kinetic after vaccination to the COVID-19 coronavirus by measurements of specific and neutralizant antibodies for spike antigenic sequences . This work will allow us to follow the efficacy and tolerance of the vaccine over a year, to evaluate the antibody profile, their kinetics, the fraction of neutralising antibodies and will also allow us to understand the attitudes to be taken to ensure the best protection for our staff

Detailed Description
-----------------
Our objective is to follow the hospital staff after vaccination, for this we will include two groups of participants: G1: vaccinated staff who did not contract the virus (at the date of vaccination) and who had a serology <0 at least at D7 of the date of vaccination dose 1 (known serological value) G2: vaccinated personnel who have contracted the virus with a PCR + and who have positive serology at least at D7 of the date of vaccination (known serological value)

Official Title
-----------------
Estimation of Dynamics of Humoral Immunity in COVID-19 Vaccined Health Care Workers

Conditions
-----------------
Tunis Military Hospital Staff Vaccinated Against Covid 19

Intervention / Treatment
-----------------
* Other: Blood sampling (4 per year)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: RB-approved informed consent, age 18 years or older, male or female, anyone considering COVID-19 vaccination or anyone that has received COVID-19 vaccination. Subjects can enroll at anytime after vaccination even though they may not have enrolled before vaccination. Sampling Frequency and timing: Up to 8 total samples in 12 months - Exclusion Criteria: Exclusion: Failure to provide informed consent -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Blood sampling (4 per year)|Blood sampling (4 per year)|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vaccine effectiveness | Vaccine effectiveness as measured by the number of positive PCRs in one year | 1 year | 
| Vaccine effectiveness | antibody kinetics | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the tolerance of the vaccine | post-vaccination adverse event | 1 year |
The Mollie Study, a Study to Evaluate the Safety and Efficacy of the Mollie Medical Device

Study Overview
=================
Brief Summary
-----------------
Study to evaluate the use of a medical device in relieving collision dyspareunia

Official Title
-----------------
DAT: Dyspareunia Alleviation Trial

Conditions
-----------------
Dyspareunia

Intervention / Treatment
-----------------
* Device: Mollie device


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Females 18 years of age and older with a diagnosis of collision dyspareunia - Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Treatment arm and sham arm
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Treatment<br>Actual treatment device | Device: Mollie device<br>* medical device<br>* Other names: Sham;|
| Sham Comparator: Sham<br>Sham/placebo device | Device: Mollie device<br>* medical device<br>* Other names: Sham;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dyspareunia Alleviation | The Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v.4.0, Change from Baseline in Pain Scores on the Visual Analog Scale at 13 Weeks | 12 weeks |
Evaluation of Covid 19 Knowledge Anxiety and Expectation Levels of Turkish Physicians, Survey Study

Study Overview
=================
Brief Summary
-----------------
It is aimed to measure the general health information of Turkish physicians about covid 19 pandemic, to evaluate anxiety levels and to evaluate future expectations in this period.

Official Title
-----------------
Evaluation of Covid 19 Knowledge Anxiety and Expectation Levels of Turkish Physicians, Survey Study

Conditions
-----------------
COVID-19, Physician-Patient Relations

Intervention / Treatment
-----------------
* Behavioral: turkish physicians


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: turkish physicians work active in pandemic hospital Exclusion Criteria: work in another country retired physicians

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: turkish physicians|turkish physicians, who work active in pandemic hospital.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of covid-19 knowledge level of turkish physicians | beck depression scale The BDI inventory has maximum of 63 and minimum of 0 scores: (0-10): Are considered normal ups and downs (11-16): Mild mood disturbance (17-20): Borderline clinical depression (21-30): Moderate depression, (31-40): Severe depression, Over 40: Extreme depression. A persistent score of !17, requires psychiatric treatment | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| what they think about the future | Turkish physicians write their thoughts about the health system after covid 19 with their own sentences | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
covid-19, turkish physicians